Checkpoint Therapeutics, Inc. (CKPT) - Forward P/S Multiple
Checkpoint Therapeutics is implementing robotic systems and AI to accelerate the discovery of immuno-oncology agents. The projected P/S ratio reflects the current market valuation, with the metric standing at 9239.00. Digital data analysis enables the company to efficiently manage global research. The market share capture strategy is based on discount pricing for the drug following FDA approval.
Financial and market metric breakdowns for Checkpoint Therapeutics Inc (CKPT)
- current price and projected stock value:
- market capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Debt to Equity Checkpoint Therapeutics|CKPT - Long-Term Liabilities to Equity|Short-Term Debt to Equity Checkpoint Therapeutics|CKPT - Company Cumulative Debt|Debts to Book Capitalization Checkpoint Therapeutics Inc|CKPT - Long-Term Debt Volume|Company Short-Term Debt Checkpoint Therapeutics|Quick Liquidity Indicator checkpointtx.com
- financial results and valuation multiples details:
CKPT - Profit After Payment of Taxes|Future Profit Checkpoint Therapeutics|CKPT - Company Value to Net Income|Projected Price to Earnings Checkpoint Therapeutics, Inc|CKPT - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Checkpoint Therapeutics Inc|CKPT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Checkpoint Therapeutics|CKPT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months checkpointtx.com|CKPT - Earnings per share increase in current year|Earnings growth forecast for next year Checkpoint Therapeutics
- sales and revenue data:
Initial company analysis:Checkpoint Therapeutics, Inc. CKPT
The forward P/S reflects the ratio of current market capitalization to expected revenue, capturing the trend of market expectations regarding business value per unit of sales. By analyzing the forward P/S chart for Checkpoint Therapeutics (CKPT), an investor assesses the justification for the premium over assets, considering the strategy of aggressive oncology market capture through price dumping as the drug enters the commercialization stage following FDA approval.
Analysis of competing companies
Forward P/S Multiple ONC (BeiGene)|Forward Price to Sales HALO|RevMed - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ascentage Pharma Corp|CGON: Forward P/S Multiple|Forward Price-to-Revenue Multiple urogen.com|Price-to-Projected Revenue Ratio Bicara Therapeutics|Forward P/S Multiple Personalis Inc|Price-to-Projected Revenue Ratio Erasca Corp (ERAS)|DCTH: Future Price to Revenue|Price-to-Projected Revenue Ratio Y-mAbs Therapeutics YMAB|aurabiosciences.com (AURA) - Market Cap to Future Revenue Ratio|Candel - Forward P/S Multiple|Market Cap to Expected Sales Ratio Accuray Inc ARAY|sellaslifesciences.com (SLS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ACTU|Forward Price-to-Revenue Multiple CTOR|HURA (TuHURA) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Forward Price to Sales|Aadi Bioscience - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio TCRX (TScan Therapeutics Inc)|Champions Oncology Corp - Forward P/S Multiple|Forward Price to Sales XBIT (XBiotech Inc.)|CVM: Forward P/S Multiple|Market Cap to Future Revenue Ratio OS Therapies Inc. (OSTX)|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|ARTV: Forward Price to Sales|Forward P/S Multiple ANL|Forward P/S Multiple verupharma.com (VERU)|Price-to-Projected Revenue Ratio Tempest Therapeutics, Inc. TPST|XLO (Xilio Therapeutics Inc) - Future Price to Revenue|Enochian BioSciences - Forward P/S Multiple|Market Cap to Future Revenue Ratio Mural Oncology plc|KAPA (kairospharma.com) - Forward Price-to-Revenue Multiple|OnKure Therapeutics (OKUR) - Forward P/S Multiple|Forward Price-to-Revenue Multiple GDTC|CRIS (Curis Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple APLM|Market Cap to Expected Sales Ratio Tharimmune Corporation|Forward P/S Multiple ADVB (Advanced Biomed)|GNPX - Forward Price-to-Revenue Multiple|CLDI - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Sunshine Biopharma Inc. SBFM|XBIO: Forward P/S Multiple|Forward Price-to-Revenue Multiple Salarius Pharma|Price-to-Projected Revenue Ratio Purple Biotech|Forward P/S Multiple AON|Price-to-Projected Revenue Ratio BeiGene (BGNE)|ELEV: Future Price to Revenue|iCAD - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio IKNA (Ikena Oncology Inc.)|Notable Labs, Ltd. - Forward P/S Multiple|Viracta Therapeutics (VIRX) - Forward Price-to-Revenue Multiple|MOR: Forward P/S Multiple|NAYA Biosciences Inc (NAYA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Ascentage Pharma Group Ltd
